MAP3K1

Quality 0.50 · 2 views · Updated 2 months ago

Protein-coding gene in the species Homo sapiens

title: "MAP3K1" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public tags: ["mitogen-activated-protein-kinases", "ec-2.7.11", "biomarkers"] description: "Protein-coding gene in the species Homo sapiens" topic_path: "general/mitogen-activated-protein-kinases" source: "https://en.wikipedia.org/wiki/MAP3K1" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0

::summary Protein-coding gene in the species Homo sapiens ::

Mitogen-activated protein kinase kinase kinase 1 (MAP3K1) is a signal transduction enzyme that in humans is encoded by the autosomal MAP3K1 gene.

Function

MAP3K1 (or MEKK1) is a serine/threonine kinase and ubiquitin ligase that performs a pivotal role in a network of enzymes integrating cellular receptor responses to a number of mitogenic and metabolic stimuli, including: TNF receptor superfamily (TNFRs), T-cell receptor (TCR), Epidermal growth factor receptor (EGFR), and TGF beta receptor (TGFβR). Mitogen-activated protein kinase kinases (MAP2Ks) are substrates for direct phosphorylation by the MAP3K1 protein kinase. The MAP3K1 kinase domain may also be a modest activator of IκB kinase activation. The MAP3K1 E3 ubiquitin ligase recruits a ubiquitin-conjugating enzyme (including UBE2D2, UBE2D3, and UBE2N:UBE2V1) that has been loaded with ubiquitin, interacts with its substrates, and facilitates the transfer of ubiquitin from the ubiquitin-conjugating enzyme onto its substrates. Genetics has revealed that MAP3K1 is important in: embryonic development, tumorigenesis, cell growth, cell migration, cytokine production, and humoral immunity. MAP3K1 mutants were identified in breast cancer by GWAS.

Structure

MAP3K1 contains a protein kinase domain, PHD finger (which has a RING finger domain-like structure) that serves as an E3 ubiquitin ligase, and scaffold protein regions that mediate protein–protein interactions.

Genetic analyses in murine and avian models

MAP3K1 is highly conserved in Euteleostomi. The spontaneous recessive lidgap-Gates mutation (deletion of Map3k1 exons 2–9, initially described in the 1960s) identified on the SELH/Bc mouse strain causes the same open-eyelids-at-birth mutational phenotype as the gene knockout mutations of the mouse (but not human) MAP3K1 homolog (Map3k1) and also co-maps to distal Chromosome 13. MAP3K1 was analysed genetically by targeted mutagenesis using transgenic mice (C57BL/6 and C57BL/6 × 129 backgrounds), embryonic stem cells, and the DT40 cell line to identify genetic traits.

::data[format=table]

Map3k1 mutantSpeciesGenetic modelReferences
Deletion of 132 codons in Map3k1 exon 1Mus musculusTransgenic mouse and embryonic stem cells
Deletion kinase domainMus musculusTransgenic mouse and embryonic stem cells
Point mutations in Map3k1 exon 7 encoding E3 ubiquitin ligaseMus musculusTransgenic mouse and embryonic stem cells
T cell-specific deletion generated by Lck promoter-driven CreMus musculusTransgenic mouse
Deletion carboxyl-terminusGallus gallus domesticusLymphoblast cell line
::

Mechanism of MAPK activation by MAP3K1

MAP3K1 contains multiple amino acid sites that are phosphorylated and ubiquitinated. Early biochemical analysis demonstrated that triple co-expression of MAP3K1, MAP2K and MAPK in bacterial cells was sufficient for the activation of MAPK. Later analysis of syngenic mice that harbour mutations in TRAF2, UBE2N, Map3k1 and Map3k7 identified critical regulators of cytokine-induced MAPK signal transduction in B cells. Cytokine signaling through MAP3K1 utilises two-stage cell signaling to recruit the signal transduction mechanism to cytokine receptors and then release the signal transduction components, altered by post-translational modification, from the cellular membrane to activate MAPKs. Genetic analysis has demonstrated that the E3 Ub ligase  and the kinase domains of MAP3K1 are required for MAPK activation.

::figure[src="https://upload.wikimedia.org/wikipedia/commons/9/91/MAP3K1_2-stage_signaling.png" caption="'''MAP3K1 signal transduction'''. '''A'''. Cytokine receptor prior to ligation by cytokine. '''B'''. Recruitment of TRAFs 2, 3 and 6 to the cytokine receptor. '''C'''. Ubiquitination of TRAFs. Recruitment of MAP3K1 and MAP3K7 signaling modules to TRAFs and scaffolding. '''D'''. Degradation of canonical Ubiquitin-TRAF3 by the proteasome, release of non-canonical Ubiquitin-TRAF2 and -MAP3Ks into the cytoplasm, and activation of MAP2K signaling."] ::

Cancers, other diseases and therapeutic targeting

MAP3K1 is a biomarker mutated in 3.24% of all human cancers. MAP3K1 has been associated with several diseases in non-syngeneic human populations, including: breast cancer, adenocarcinoma of the prostate, sarcomatoid hepatocellular carcinoma, acute respiratory distress syndrome, Langerhans cell histiocytosis, and 46,XY disorders of sex development. E6201 is an enzyme inhibitor of MAP3K1 that shows cross-specificity with MAP2K1.

Interaction partners

MAP3K1 has been shown to interact with a number of proteins, including:

References

References

  1. (November 1995). "Mapping of the MEK kinase gene (Mekk) to mouse chromosome 13 and human chromosome 5". Mammalian Genome.
  2. "Entrez Gene: MAP3K1 mitogen-activated protein kinase kinase kinase 1".
  3. (November 1998). "The TAO of MEKK". Frontiers in Bioscience.
  4. (April 2015). "A RING to rule them all? Insights into the Map3k1 PHD motif provide a new mechanistic understanding into the diverse roles of Map3k1". Cell Death and Differentiation.
  5. (December 1994). "Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK". Science.
  6. (2005). "From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance". IUBMB Life.
  7. (August 1998). "JNK or IKK, AP-1 or NF-kappaB, which are the targets for MEK kinase 1 action?". Proceedings of the National Academy of Sciences of the United States of America.
  8. (November 2014). "The MEKK1 PHD ubiquitinates TAB1 to activate MAPKs in response to cytokines". The EMBO Journal.
  9. (June 2007). "Genome-wide association study identifies novel breast cancer susceptibility loci". Nature.
  10. "Q13233 (M3K1_HUMAN)". Swiss Institute of Bioinformatics.
  11. (22–29 December 1994). "Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1". Nature.
  12. (May 2002). "The PHD domain of MEKK1 acts as an E3 ubiquitin ligase and mediates ubiquitination and degradation of ERK1/2". Molecular Cell.
  13. (September 2020). "A cryptic tubulin-binding domain links MEKK1 to curved tubulin protomers". Proceedings of the National Academy of Sciences of the United States of America.
  14. "HomoloGene - NCBI".
  15. (January 2005). "The open-eyelid mutation, lidgap-Gates, is an eight-exon deletion in the mouse Map3k1 gene". Genomics.
  16. (December 1998). "Role of MEKK1 in cell survival and activation of JNK and ERK pathways defined by targeted gene disruption". Science.
  17. (June 2000). "MEK kinase 1 gene disruption alters cell migration and c-Jun NH2-terminal kinase regulation but does not cause a measurable defect in NF-kappa B activation". Proceedings of the National Academy of Sciences of the United States of America.
  18. (April 1999). "MEK kinase 1 (MEKK1) transduces c-Jun NH2-terminal kinase activation in response to changes in the microtubule cytoskeleton". The Journal of Biological Chemistry.
  19. (December 1999). "MEKK1 suppresses oxidative stress-induced apoptosis of embryonic stem cell-derived cardiac myocytes". Proceedings of the National Academy of Sciences of the United States of America.
  20. (September 2003). "A role for MEK kinase 1 in TGF-beta/activin-induced epithelium movement and embryonic eyelid closure". The EMBO Journal.
  21. (October 2004). "Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch". Science.
  22. (January 2007). "Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production". Nature Immunology.
  23. (November 2005). "MEK kinase 1 activity is required for definitive erythropoiesis in the mouse fetal liver". Blood.
  24. (August 2006). "MEK kinase 1 is a negative regulator of virus-specific CD8(+) T cells". European Journal of Immunology.
  25. (January 2016). "T-Cell-Specific Deletion of Map3k1 Reveals the Critical Role for Mekk1 and Jnks in Cdkn1b-Dependent Proliferative Expansion". Cell Reports.
  26. (November 2001). "MEKK1 is essential for DT40 cell apoptosis in response to microtubule disruption". Molecular and Cellular Biology.
  27. (February 2011). "Apoptosis induced by cytoskeletal disruption requires distinct domains of MEKK1". PLOS ONE.
  28. "MEKK1 (human)".
  29. (April 1997). "Reconstitution of mitogen-activated protein kinase phosphorylation cascades in bacteria. Efficient synthesis of active protein kinases". The Journal of Biological Chemistry.
  30. (November 1997). "TRAF2 is essential for JNK but not NF-kappaB activation and regulates lymphocyte proliferation and survival". Immunity.
  31. (September 2006). "Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling". Nature Immunology.
  32. (November 2005). "Essential function for the kinase TAK1 in innate and adaptive immune responses". Nature Immunology.
  33. (January 2007). "Kinase MEKK1 is required for CD40-dependent activation of the kinases Jnk and p38, germinal center formation, B cell proliferation and antibody production". Nature Immunology.
  34. (August 2008). "Essential cytoplasmic translocation of a cytokine receptor-assembled signaling complex". Science.
  35. (March 2009). "TNFR signaling: ubiquitin-conjugated TRAFfic signals control stop-and-go for MAPK signaling complexes". Immunological Reviews.
  36. (May 2000). "MEK kinase 1 is critically required for c-Jun N-terminal kinase activation by proinflammatory stimuli and growth factor-induced cell migration". Proceedings of the National Academy of Sciences of the United States of America.
  37. "MAP3K1 - My Cancer Genome".
  38. "MAP3K1 mitogen-activated protein kinase kinase kinase 1 [Homo sapiens (human)] - Gene - NCBI".
  39. (May 2012). "The landscape of cancer genes and mutational processes in breast cancer". Nature.
  40. (May 2021). "First case of ductal adenocarcinoma of the prostate with MAP3K1 homozygous deletion". IJU Case Reports.
  41. (September 2021). "Sarcomatoid hepatocellular carcinoma: From clinical features to cancer genome". Cancer Medicine.
  42. (January 2018). "Genetic Variation in MAP3K1 Associates with Ventilator-Free Days in Acute Respiratory Distress Syndrome". American Journal of Respiratory Cell and Molecular Biology.
  43. (June 2015). "MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis". Genes, Chromosomes & Cancer.
  44. (December 2010). "Mutations in MAP3K1 cause 46,XY disorders of sex development and implicate a common signal transduction pathway in human testis determination". American Journal of Human Genetics.
  45. (November 2009). "E6201 [(3S,4R,5Z,8S,9S,11E)-14-(ethylamino)-8, 9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione], a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1: in vitro characterization of its anti-inflammatory and antihyperproliferative activities". The Journal of Pharmacology and Experimental Therapeutics.
  46. (May 2002). "Casein kinase I and casein kinase II differentially regulate axin function in Wnt and JNK pathways". The Journal of Biological Chemistry.
  47. (August 2000). "Dimerization choices control the ability of axin and dishevelled to activate c-Jun N-terminal kinase/stress-activated protein kinase". The Journal of Biological Chemistry.
  48. (December 2000). "MEKK1 binds raf-1 and the ERK2 cascade components". The Journal of Biological Chemistry.
  49. (September 1998). "Grb2 interaction with MEK-kinase 1 is involved in regulation of Jun-kinase activities in response to epidermal growth factor". The Journal of Biological Chemistry.
  50. (December 1997). "MEKK1 binds directly to the c-Jun N-terminal kinases/stress-activated protein kinases". The Journal of Biological Chemistry.
  51. (May 1999). "Signaling by proinflammatory cytokines: oligomerization of TRAF2 and TRAF6 is sufficient for JNK and IKK activation and target gene induction via an amino-terminal effector domain". Genes & Development.
  52. (April 1998). "hUBC9 associates with MEKK1 and type I TNF-alpha receptor and stimulates NFkappaB activity". FEBS Letters.
  53. (November 2014). "The MEKK1 PHD ubiquitinates TAB1 to activate MAPKs in response to cytokines". The EMBO Journal.
  54. (January 2004). "RhoA binds to the amino terminus of MEKK1 and regulates its kinase activity". The Journal of Biological Chemistry.
  55. (August 1997). "MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42". The EMBO Journal.
  56. (August 2002). "p115 Rho GTPase activating protein interacts with MEKK1". Journal of Cellular Physiology.
  57. (November 1998). "JNKK1 organizes a MAP kinase module through specific and sequential interactions with upstream and downstream components mediated by its amino-terminal extension". Genes & Development.
  58. (February 2003). "MEK kinase 1 interacts with focal adhesion kinase and regulates insulin receptor substrate-1 expression". The Journal of Biological Chemistry.
  59. (January 2015). "Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1". American Journal of Human Genetics.

::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::

mitogen-activated-protein-kinasesec-2.7.11biomarkers